This finding agreed with the outcomes of other previous studies that reported the inhibition of p38 and the Erk1/2 MAPKs pathway resulting in the upregulation of ROS and thereby sensitizing human tumor cells to cisplatin-induced cell death [32]. The gene discussed is MAPK3; the disease is neoplasm.